References
- Rinehart KL, Holt TG, Fregeau NL, et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 1990; 55: 4512-4515.
- Guan Y, Sakai R, Rinehart KL, Wang AHJ. Molecular and crystal structures of ecteinascidins: Potent antitumor com-pounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 1993; 10: 793–818.
- Moore II, BM, Seaman FC, Hurley LH. NMR-based model of an ecteinascidin 743-DNA adduct J Am Chem Soc 1997; 119: 5475-5476.
- Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selec-tive alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996; 35: 13303–13309.
- Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999; 42: 2493-2497.
- Bonfanti M, La Valle E, Fernandez Sousa Faro JM, Faircloth G, Caretti G, D'Incalci M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anti-Cancer Drug Des 1999; 14: 179–186.
- Minuzzo M, Marchini S, Broggini M, Faircloth CT, D'Incalci M, Mantovani R. Interference of transcriptional acti-vation by the anti-neoplastic drug ET-743. Proc Nati Acad Sci USA 2000; 97: 6780-6784.
- Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Nati Acad Sci USA, 2000; 97: 6775-6779.
- Albella B, Faircloth G, Lopez-Lazaro L, Guzman C, Jimeno J, Bueren JA. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results. Eur J Cancer, 2002; 38: 1395–1404.
- Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 1977-1983.
- Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001; 7: 961–966.
- Erba E, Cavallaro E, Damia G, et al. The unique bio-logical features of the marine product YondelisTm (ET-743, tra-bectedin) are shared by its analog PM00128 which lacks the C ring. Oncol Res, in press.
- Sakai R, Rinehart KL, Kishore V, et al. Structure—activity relationships of the didemnins. J Med Chem 1996; 39: 2819–2834.
- da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol 2001; 1: 364–369.
- Erba E, Bassano L, Di Liberti G, et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by apli-dine. Br J Cancer 2002; 86: 1510–1517.
- Erba E, Serafini M, Gaipa G, et al. Effect of Aplidin in acute lymphoblastic leukaemia cells. Br J Cancer 2003; 89: 763–773.
- Broggini M, Marchini SV, Galliera E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (fit-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003; 17: 52–59.
- Marchini S, Chiorino G, Faircloth CT, D'Incalci M. Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines. J Biol Regul Homeost Agents 2002; 16: 241–248.
- Taraboletti G, Poli M, Dossi R, et al. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 2004; 90: 2418–2424.